Gene Expression Analysis Market based on by Products (Consumable, Instruments), by Application (Drug Discovery, Diagnostics), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others), Regional Outlook– Global Forecast up to 2030
In the recent decade, the high cost of sequencing constituted a significant barrier to market expansion. The Human Genome Project needed USD 2.7 billion in funding in 2003 to sequence the first human genome. However, significant technical advancements in the field of genomics have occurred, with the goal of improving the speed and lowering the costs involved with sequencing.
For many years, the NHGRI (National Human Genome Research Institute, United States) has tracked sequencing prices at its many sponsored genome sequencing centres and calculated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, generating a finished human genome sequence would have cost more than USD 20-25 million, whereas by late 2015, the cost to generate a high-quality whole human genome sequence draft had fallen below USD 1,500, and the cost to generate a whole-exome sequence was generally less than USD 1,000.
Major firms in the gene expression sector are continually bringing new and improved technologies to the market. This enables the industry to see the introduction of more economical testing services. In January 2017, Illumina (US) unveiled the NovaSeq Series, which is predicted to reduce the cost of sequencing a genome/transcriptome to as little as USD 100 in the next years.
The lower cost of sequencing is likely to open up a slew of new prospects for healthcare players. For example, the low cost of sequencing would allow researchers to sequence the genomes of thousands of people, resulting in a better data set for determining the aetiology of diseases. Furthermore, the decreased cost would allow persons with uncommon disorders to be evaluated and treated more rapidly. As a result, the considerable decrease in sequencing costs is likely to be a major driver driving the growth of the gene expression analysis market.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Gene Expression Analysis Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Gene Expression Analysis Market , as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Gene Expression Analysis Market based on End User:
Next-Generation Sequencing (NGS) is a technique for determining the sequence of DNA or RNA in order to analyse genetic changes linked with illness. It is also known as massively parallel sequencing since it allows the sequencing to determine the sequencing of millions of DNA sequences at the same time.
Next-generation sequencing is predicted to rise significantly throughout the forecast period due to reasons such as an increase in the application of NGS technology in clinical diagnostics, as well as the speed, affordability, and accuracy of the sequencing process. Furthermore, the benefit of NGS over Sanger's sequencing approach, which gives accuracy results with modest sample input, is boosting market expansion.
The growing usage of next-generation sequencing technology in applications such as biomarker identification, cancer research, and personalised medicine is driving market expansion. For example, the rapid emergence of next-generation sequencing technology has revolutionised genomics and medical diagnosis, shifting from a gene-by-gene approach to a precision model based on syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). According to the Centres for Disease Control and Prevention, more than 60 million people globally will have their genomes sequenced by 2025, as nations take the initiative to analyse big populations. Furthermore, cell-free plasma next-generation sequencing (cfNGS) is used to diagnose viral, bacterial, and fungal infections in the blood by detecting pathogen DNA.
Furthermore, several initiatives launched by universities, academic and research organisations, and research institutes to employ next-generation sequencing technology to pinpoint the underlying cause of illnesses are expected to boost the segment's growth. For example, Roche will deploy the AVENIO Edge System in December 2021 to improve next-generation sequencing (NGS) technology. Cerba Research, meanwhile, introduced two COVID-19 exploratory tools, PCR-based and Next-Generation Sequencing-based, in January 2021, to increase research for vaccine development against infectious illnesses, including COVID-19. The next-generation sequencing-based assay considerably simplified whole-genome sequencing of respiratory viruses including SARS-CoV-2. Such advancements provide a significant boost to clinical research and organisations who are using next-generation sequencing as their foundation for innovation.
The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some market players are QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Promega Corporation, and Luminex Corporation. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.
For many years, the NHGRI (National Human Genome Research Institute, United States) has tracked sequencing prices at its many sponsored genome sequencing centres and calculated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, generating a finished human genome sequence would have cost more than USD 20-25 million, whereas by late 2015, the cost to generate a high-quality whole human genome sequence draft had fallen below USD 1,500, and the cost to generate a whole-exome sequence was generally less than USD 1,000.
Major firms in the gene expression sector are continually bringing new and improved technologies to the market. This enables the industry to see the introduction of more economical testing services. In January 2017, Illumina (US) unveiled the NovaSeq Series, which is predicted to reduce the cost of sequencing a genome/transcriptome to as little as USD 100 in the next years.
The lower cost of sequencing is likely to open up a slew of new prospects for healthcare players. For example, the low cost of sequencing would allow researchers to sequence the genomes of thousands of people, resulting in a better data set for determining the aetiology of diseases. Furthermore, the decreased cost would allow persons with uncommon disorders to be evaluated and treated more rapidly. As a result, the considerable decrease in sequencing costs is likely to be a major driver driving the growth of the gene expression analysis market.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Gene Expression Analysis Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Gene Expression Analysis Market , as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Gene Expression Analysis Market based on End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
- Consumable
- Instruments
- Type
- Polymerase Chain Reaction
- Next Generation Sequencing
- DNA Microarrays
- Others
- Drug Discovery
- Diagnostics
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Next-Generation Sequencing (NGS) is a technique for determining the sequence of DNA or RNA in order to analyse genetic changes linked with illness. It is also known as massively parallel sequencing since it allows the sequencing to determine the sequencing of millions of DNA sequences at the same time.
Next-generation sequencing is predicted to rise significantly throughout the forecast period due to reasons such as an increase in the application of NGS technology in clinical diagnostics, as well as the speed, affordability, and accuracy of the sequencing process. Furthermore, the benefit of NGS over Sanger's sequencing approach, which gives accuracy results with modest sample input, is boosting market expansion.
The growing usage of next-generation sequencing technology in applications such as biomarker identification, cancer research, and personalised medicine is driving market expansion. For example, the rapid emergence of next-generation sequencing technology has revolutionised genomics and medical diagnosis, shifting from a gene-by-gene approach to a precision model based on syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). According to the Centres for Disease Control and Prevention, more than 60 million people globally will have their genomes sequenced by 2025, as nations take the initiative to analyse big populations. Furthermore, cell-free plasma next-generation sequencing (cfNGS) is used to diagnose viral, bacterial, and fungal infections in the blood by detecting pathogen DNA.
Furthermore, several initiatives launched by universities, academic and research organisations, and research institutes to employ next-generation sequencing technology to pinpoint the underlying cause of illnesses are expected to boost the segment's growth. For example, Roche will deploy the AVENIO Edge System in December 2021 to improve next-generation sequencing (NGS) technology. Cerba Research, meanwhile, introduced two COVID-19 exploratory tools, PCR-based and Next-Generation Sequencing-based, in January 2021, to increase research for vaccine development against infectious illnesses, including COVID-19. The next-generation sequencing-based assay considerably simplified whole-genome sequencing of respiratory viruses including SARS-CoV-2. Such advancements provide a significant boost to clinical research and organisations who are using next-generation sequencing as their foundation for innovation.
The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some market players are QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Promega Corporation, and Luminex Corporation. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.
- This report illustrates the most vital attributes of the Gene Expression Analysis Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Gene Expression Analysis Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Gene Expression Analysis Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Gene Expression Analysis Market.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. END USER: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Pharmaceutical and Biotechnology Companies
5.3. Academic and Research Institutes
5.4. Others
6. PRODUCT: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Consumable
6.3. Instruments
7. APPLICATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Drug Discovery
7.3. Diagnostics
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. QIAGEN
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F. Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. PerkinElmer Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Bio-Rad Laboratories, Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Promega Corporation
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. PACBIO
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Illumina Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Agilent Technologies Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Thermo Fisher Scientific Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Oxford Nanopore Technologies
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
Tables
TABLE 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. QIAGEN : FINANCIALS
TABLE 84. QIAGEN : PRODUCTS & SERVICES
TABLE 85. QIAGEN : RECENT DEVELOPMENTS
TABLE 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 89. PERKINELMER INC.: FINANCIALS
TABLE 90. PERKINELMER INC.: PRODUCTS & SERVICES
TABLE 91. PERKINELMER INC.: RECENT DEVELOPMENTS
TABLE 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
TABLE 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 95. PROMEGA CORPORATION: FINANCIALS
TABLE 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
TABLE 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
TABLE 98. PACBIO: FINANCIALS
TABLE 99. PACBIO: PRODUCTS & SERVICES
TABLE 100. PACBIO: RECENT DEVELOPMENTS
TABLE 101. ILLUMINA INC. : FINANCIALS
TABLE 102. ILLUMINA INC. : PRODUCTS & SERVICES
TABLE 103. ILLUMINA INC. : DEVELOPMENTS
TABLE 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
TABLE 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS
Charts
CHART. 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 83. QIAGEN : FINANCIALS
CHART. 84. QIAGEN : PRODUCTS & SERVICES
CHART. 85. QIAGEN : RECENT DEVELOPMENTS
CHART. 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
CHART. 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
CHART. 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
CHART. 89. PERKINELMER INC.: FINANCIALS
CHART. 90. PERKINELMER INC.: PRODUCTS & SERVICES
CHART. 91. PERKINELMER INC.: RECENT DEVELOPMENTS
CHART. 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
CHART. 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
CHART. 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
CHART. 95. PROMEGA CORPORATION: FINANCIALS
CHART. 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
CHART. 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
CHART. 98. PACBIO: FINANCIALS
CHART. 99. PACBIO: PRODUCTS & SERVICES
CHART. 100. PACBIO: RECENT DEVELOPMENTS
CHART. 101. ILLUMINA INC. : FINANCIALS
CHART. 102. ILLUMINA INC. : PRODUCTS & SERVICES
CHART. 103. ILLUMINA INC. : DEVELOPMENTS
CHART. 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
CHART. 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
CHART. 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
CHART. 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
CHART. 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
CHART. 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
CHART. 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
CHART. 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
CHART. 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. END USER: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Pharmaceutical and Biotechnology Companies
5.3. Academic and Research Institutes
5.4. Others
6. PRODUCT: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Consumable
6.3. Instruments
7. APPLICATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Drug Discovery
7.3. Diagnostics
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. QIAGEN
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F. Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. PerkinElmer Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Bio-Rad Laboratories, Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Promega Corporation
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. PACBIO
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Illumina Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Agilent Technologies Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Thermo Fisher Scientific Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Oxford Nanopore Technologies
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
Tables
TABLE 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. QIAGEN : FINANCIALS
TABLE 84. QIAGEN : PRODUCTS & SERVICES
TABLE 85. QIAGEN : RECENT DEVELOPMENTS
TABLE 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 89. PERKINELMER INC.: FINANCIALS
TABLE 90. PERKINELMER INC.: PRODUCTS & SERVICES
TABLE 91. PERKINELMER INC.: RECENT DEVELOPMENTS
TABLE 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
TABLE 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 95. PROMEGA CORPORATION: FINANCIALS
TABLE 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
TABLE 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
TABLE 98. PACBIO: FINANCIALS
TABLE 99. PACBIO: PRODUCTS & SERVICES
TABLE 100. PACBIO: RECENT DEVELOPMENTS
TABLE 101. ILLUMINA INC. : FINANCIALS
TABLE 102. ILLUMINA INC. : PRODUCTS & SERVICES
TABLE 103. ILLUMINA INC. : DEVELOPMENTS
TABLE 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
TABLE 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS
Charts
CHART. 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 83. QIAGEN : FINANCIALS
CHART. 84. QIAGEN : PRODUCTS & SERVICES
CHART. 85. QIAGEN : RECENT DEVELOPMENTS
CHART. 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
CHART. 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
CHART. 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
CHART. 89. PERKINELMER INC.: FINANCIALS
CHART. 90. PERKINELMER INC.: PRODUCTS & SERVICES
CHART. 91. PERKINELMER INC.: RECENT DEVELOPMENTS
CHART. 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
CHART. 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
CHART. 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
CHART. 95. PROMEGA CORPORATION: FINANCIALS
CHART. 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
CHART. 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
CHART. 98. PACBIO: FINANCIALS
CHART. 99. PACBIO: PRODUCTS & SERVICES
CHART. 100. PACBIO: RECENT DEVELOPMENTS
CHART. 101. ILLUMINA INC. : FINANCIALS
CHART. 102. ILLUMINA INC. : PRODUCTS & SERVICES
CHART. 103. ILLUMINA INC. : DEVELOPMENTS
CHART. 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
CHART. 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
CHART. 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
CHART. 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
CHART. 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
CHART. 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
CHART. 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
CHART. 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
CHART. 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS
